From: Estimating the burden of antimicrobial resistance: a systematic literature review
Study | Exposure Group | Control Group | Country | Method | Excess Cost Estimate (2013 USD) |
---|---|---|---|---|---|
Cost per case | |||||
[109] | CRAB in Columbia | Carbapenem susceptible A. baumannii | Columbia | Regression | 4,583a |
[124] | ESBL+ E. coli & Klebsiella species UTI | ESBL- E. coli & Klebsiella species UTI | USA | Significance Tests | 3,237a |
[125] | ESBL+ E.coli BSI | ESBL- E.coli BSI | Germany | Matching | -2081 |
[49] | ESBL+ Enterobacteriaceae BSI | ESBL- Enterobacteriaceae BSI | Switzerland | Multistate model | 10,154 |
[45] | ESBL+ UTI | ESBL- UTI | Spain | Matching & Regression | 3146† |
[126] | ESBL+ and/or beta-lactamases resistant UTI | Susceptible UTI | Turkey | Significance Tests | 90a |
[126] | Ciprofloxacin resistant UTI | Ciprofloxacin susceptible UTI | Turkey | Significance Tests | 114a |
[127] | MDR A. baumannii BSI | Susceptible A. baumannii BSI | Turkey | Significance Tests | 15,365 |
[58] | MRSA | Non-exposure inpatients | Germany | Stepwise Calculations | 11,878 |
[53] | MRSA breast abscess | MSSA breast abscess | USA | Matching | 515 |
[128] | MRSA BSI | Non-exposure BSI | South Korea | Stepwise Calculations | 5216 |
[129] | MRSA BSI (survivors) | Non-nosocomial-infected patients | South Korea | Matching | 11,627 |
[129] | MRSA BSI (non-survivors) | Non-nosocomial-infected patients | South Korea | Matching | 15,254 |
[51] | MRSA infections | Non-exposure inpatients | USA | Matching | 28,553a |
[130] | MRSA colonisation & infection | Non-exposure inpatients | USA | Matching | 12,167a |
[131] | Resistant BSI | Susceptible BSI | India | Significance Tests | 912a |
[132] | Carbapenem-resistant device associated healthcare acquired infections ICU patients | Non-“device associated healthcare acquired infections” ICU patients | Greece | Significance Tests | 3,884a |
[133] | VRE colonisation & infections | Non-exposure inpatients | Canada | Matching & Regression | 18,631a |
[76] | VRE BSI | VSE BSI | Australia | Matching & Regression | 30,093a |
[134] | VRE BSI in allo-HSCT recipients | Non-exposure in allo-HSCT recipients | USA | Significance Tests | 6104 |
[135] | MDR TB | Non-MDR TB | Germany | Stepwise Calculations | 86,321 |
[136] | MDR TB | Non-MDR TB | South Africa | Stepwise Calculations | 6728 |
[137] | MDR TB | Non-MDR TB | Latvia | Regression | 33291a |
[138] | XDR and pre-XDR TB | Rifampicin-mono-resistant or MDR TB | South Africa | Stepwise Calculations | 15,567 |
[136] | XDR TB | Non-“XDR or MDR” TB | South Africa | Stepwise Calculations | 26,989 |
[139] | VRE BSI in leukaemia patients | Non-exposure leukaemia patients | USA | Matching | 88150a |
Per-patient per-day | |||||
[50] | MRSA in Switzerland | Non-exposure inpatients | Switzerland | Multistate model | 867 |
[140] | Resistant Gram-negative Bacilli infection | Susceptible Gram-negative Bacilli infection | Singapore | Matching | 812 |
Annual cost per stated country or stated region | |||||
[57] | MRSA | No-MRSA | USA | Multistate model | 1,382,733,079 |
[141] | Resistant Streptococcus pneumonia | Susceptible Streptococcus pneumonia | USA | Multistate model | 91,773,500 |
[142] | Artemisinin resistant malaria | No-“Artemisinin resistant malaria” | High endemicity region | Multistate model | 32,000,000 |